These two cytokines are induced by type I IFN, but only IP10/CXCL10 levels were significantly higher in the RESPONDERS group when compared to the levels of the group of HC (111±60 vs 86±86, p = 0.005) and to those levels of the rest of RR-MS patients without treatment (RR-MS Remission, RR-MS Active, RELAPSES and NON RESPONDERS) (111±60 vs 75±78, p = 0.0003). Here, CXCL10 is linked to myeloid sarcoma.